+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Next Generation Cancer Diagnostics - Global Strategic Business Report

  • PDF Icon

    Report

  • 89 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5303643
The global market for Next Generation Cancer Diagnostics is estimated at US$14.9 Billion in 2023 and is projected to reach US$57.8 Billion by 2030, growing at a CAGR of 21.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the qPCR & Multiplexing Technology segment, which is expected to reach US$25.5 Billion by 2030 with a CAGR of a 22.4%. The Next Generation Sequencing Technology segment is also set to grow at 17.6% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $4.7 Billion in 2023, and China, forecasted to grow at an impressive 20.7% CAGR to reach $9.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Next Generation Cancer Diagnostics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Next Generation Cancer Diagnostics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Next Generation Cancer Diagnostics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott, Agilent Technologies, Almac Group, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 33 Featured):

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips N.V
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Next Generation Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World 7-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for qPCR & Multiplexing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 4: World 7-Year Perspective for qPCR & Multiplexing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World 7-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for LOAC & RT-PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World 7-Year Perspective for LOAC & RT-PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 10: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Biomarker Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World 7-Year Perspective for Biomarker Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for CTC Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World 7-Year Perspective for CTC Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Proteomic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 16: World 7-Year Perspective for Proteomic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Genetic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World 7-Year Perspective for Genetic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 21: World Recent Past, Current & Future Analysis for Therapeutic Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 22: World 7-Year Perspective for Therapeutic Monitoring by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World 7-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 26: World 7-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 27: World Recent Past, Current & Future Analysis for Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 28: World 7-Year Perspective for Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Risk Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: World 7-Year Perspective for Risk Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 31: World Next Generation Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 34: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 35: USA 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 36: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 37: USA 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 40: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 41: Canada 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 42: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 43: Canada 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
JAPAN
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 46: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 47: Japan 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 48: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 49: Japan 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
CHINA
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: China 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 52: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 53: China 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 54: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 55: China 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
EUROPE
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 56: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 57: Europe 7-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • Table 58: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 59: Europe 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 60: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 61: Europe 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 62: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Europe 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
FRANCE
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 64: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 65: France 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 66: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 67: France 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 68: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: France 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
GERMANY
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 70: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 71: Germany 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 72: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 73: Germany 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 74: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Germany 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
ITALY
  • Table 76: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 77: Italy 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 78: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 79: Italy 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 80: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Italy 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
UNITED KINGDOM
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 82: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 83: UK 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 84: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 85: UK 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 86: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: UK 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
REST OF EUROPE
  • Table 88: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 89: Rest of Europe 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 90: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 91: Rest of Europe 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of Europe 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
ASIA-PACIFIC
  • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 94: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 95: Asia-Pacific 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 96: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 97: Asia-Pacific 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Asia-Pacific 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
REST OF WORLD
  • Table 100: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 101: Rest of World 7-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2024 & 2030
  • Table 102: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 103: Rest of World 7-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2024 & 2030
  • Table 104: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 105: Rest of World 7-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips N.V
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

Table Information